Abstract
This article provides an overview of scientific highlights in the field of interstitial lung disease (ILD), presented at the virtual European Respiratory Society Congress 2021. A broad range of topics was discussed this year, ranging from translational and genetic aspects to novel innovations with the potential to improve the patient pathway. Early Career Members summarize a selection of interesting findings from different congress sessions, together with the leadership of Assembly 12 – Interstitial Lung Disease.
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: Sabina A. Guler reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Boehringer Ingelheim and Hoffmann-La Roche. Participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim. Disclosures made outside the submitted work.
Conflict of interest: Sara Cuevas Ocaña reports receiving support for attending meetings and/or travel from the ERS. Disclosure made outside the submitted work.
Conflict of interest: Mouhamad Nasser reports receiving consulting fees from Boehringer Ingelheim, AstraZeneca, Hoffman La Roche and Chugai, outside the submitted work.
Conflict of interest: Wim A. Wuyts reports grants or contracts received form Roche, Boehringer Ingelheim, Galapagos, NIH and Fund scientific research Flanders. Disclosures made outside the submitted work.
Conflict of interest: Marlies Wijsenbeek reports receiving grants or contracts from Hoffmann-La Roche and Boehringer Ingelheim. Consulting fees from Roche, Boehringer Ingelheim, Galapagos, Bristol Myers Squibb, Galecto and Respivant. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Boehringer Ingelheim, F. Hoffmann-La, Roche and Novartis. Support for attending meetings and/or travel from Boehringer Ingelheim and F. Hoffmann-La Roche. Participation on a Data Safety Monitoring Board for Savara and Galapagos. Unpaid; Chair of the Idiopathic Interstitial Pneumonia group of the European Respiratory Society; Member of the board of the Netherlands Respiratory Society; Member of the scientific advisory board of the European Idiopathic Pulmonary Fibrosis and related disorders federation; Chair of the educational committee of the European Reference Network for rare Lung Diseases; Advisory board of the Dutch Lungfibrosis and Sarcoidosis patient associations. Disclosures made outside the submitted work.
Conflict of interest: Antoine FROIDURE reports grants or contracts received form Roche and Boehringer Ingelheim. Consulting fees received from Boehringer Ingelheim and Roche. Disclosures made outside the submitted work.
Conflict of interest: Elena Bargagli has nothing to disclose.
Conflict of interest: Elisabetta A. Renzoni reports grants or contracts received form Boehringer Ingelheim. Consulting fees received from Boehringer Ingelheim. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Boehringer Ingelheim, Roche and Chiesi. Support for attending meetings and/or travel received from Boehringer Ingelheim. Disclosures made outside the submitted work.
Conflict of interest: Marcel Veltkamp reports receiving consulting fees from Boehringer Ingelheim. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Chiesi Pharmaceutical. Participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim and DSMB COLD study (prof. Annema, Amsterdam UMC). Disclosures made outside the submitted work.
Conflict of interest: PAOLO SPAGNOLO reports grants or contracts received from PPM SERVICES, ROCHE and BOEHRINGER. Consulting fees received from PPM SERVICES, CHIESI, NOVARTIS and PIERIS. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from BOEHRINGER, ROCHE and CHIESI. Support for attending meetings and/or travel received from PPM SERVICES AND BOEHRINGER. Participation on a Data Safety Monitoring Board or Advisory Board for GALAPAGOS. Disclosures made outside the submitted work.
Conflict of interest: Hilario NUNES reports receiving consulting fees received from Boehringer Ingelheim, Roche and Grenentech. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Boehringer Ingelheim, Roche and Grenentech. Support for attending meetings and/or travel received from Boehringer Ingelheim, Roche and Grenentech. Participation on a Data Safety Monitoring Board or Advisory Board for Galapagos and Actelion Pharmaceuticals. Other financial or non-financial interests; Investigator of clinical trial for Sanofi, Gilead, Novartis, Galecto Biotech AB and BMS. Disclosures made outside the submitted work.
Conflict of interest: Cormac McCarthy reports receiving grants or contracts from Boehringer Ingelheim. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Roche Ltd and Aerogen. Support for attending meetings and/or travel received from Boehringer Ingelheim and Rocher. Participation on a Data Safety Monitoring Board or Advisory Board for Savara Inc. Disclosures made outside the submitted work.
Conflict of interest: MARIA MOLINA MOLINA reports grants or contracts received from Roche and Boehringer Ing. Consulting fees received from Esteve-Teijin, Ferrer and Chiesi. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Boehringer Ing. Support for attending meetings and/or travel received from Boehringer Ing. Disclosures made outside the submitted work.
Conflict of interest: Francesco Bonella reports receiving consulting fees from Boehringer Ingelheim and Savara Pharma. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Boehringer Ingelheim, Fujirebio, Galapagos NV and Roche. Support for attending meetings and/or travel received from Boehringer Ingelheim and Roche. Participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim, Bristol Myers Squibb, Fujirebio, Galapagos NV, GlaxoSmithKline, Roche and Takeda. Disclosures made outside the submitted work.
Conflict of interest: Venerino Poletti has nothing to disclose.
Conflict of interest: Michael Kreuter reports receiving grants or contracts from Roche and Boehringer Ingelheim. Consulting fees received from Roche, Boehringer Ingelheim and Galapagos. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Roche and Boehringer Ingelheim. ERS Assembly 12. Disclosures made outside the submitted work.
Conflict of interest: Katerina Antoniou reports receiving consulting fees from BI and Roche. Payment of honoraria for lectures, presentations, speakers bureaus manuscript writing or educational events for BI and Roche. Support for attending meetings and/or travel received from BI and Roche. ERS Assembly 12 head. Disclosures made outside the submitted work.
Conflict of interest: Catharina C. Moor has nothing to disclose.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received November 16, 2021.
- Accepted December 4, 2021.
- Copyright ©The authors 2021
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org
